Eagle Pharmaceuticals Inc (EGRX)
0.95
+0.05
(+5.56%)
USD |
OTCM |
Nov 22, 16:00
Eagle Pharmaceuticals Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2023 | 0.2785 |
| March 31, 2023 | 0.3143 |
| December 31, 2022 | 0.2675 |
| September 30, 2022 | 0.2649 |
| June 30, 2022 | 0.2095 |
| March 31, 2022 | 0.1099 |
| December 31, 2021 | 0.1451 |
| September 30, 2021 | 0.1484 |
| June 30, 2021 | 0.1507 |
| March 31, 2021 | 0.1636 |
| December 31, 2020 | 0.1781 |
| September 30, 2020 | 0.2027 |
| June 30, 2020 | 0.1951 |
| March 31, 2020 | 0.8072 |
| December 31, 2019 | 0.2152 |
| September 30, 2019 | 0.2258 |
| June 30, 2019 | 0.2368 |
| March 31, 2019 | 0.2395 |
| December 31, 2018 | 0.2762 |
| September 30, 2018 | 0.2283 |
| Date | Value |
|---|---|
| June 30, 2018 | 0.2515 |
| March 31, 2018 | 0.2687 |
| December 31, 2017 | 0.2667 |
| September 30, 2017 | 0.286 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.1099
Minimum
Mar 2022
0.8072
Maximum
Mar 2020
0.2434
Average
0.2027
Median
Sep 2020
Debt to Equity Ratio Benchmarks
| Eli Lilly and Co | 2.185 |
| Verrica Pharmaceuticals Inc | -1.272 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 404.82M |
| Total Liabilities (Quarterly) | 152.78M |
| Shareholders Equity (Quarterly) | 252.04M |